The autoinflammatory side of recurrent pericarditis: Enlightening the pathogenesis for a more rational treatment
- PMID: 32376492
- DOI: 10.1016/j.tcm.2020.04.006
The autoinflammatory side of recurrent pericarditis: Enlightening the pathogenesis for a more rational treatment
Abstract
Recurrent pericarditis (RP) is a troublesome and debilitating complication of acute pericarditis. Although the etiopathogenesis of this condition remains unknown, an intricate overlap of autoimmune and autoinflammatory pathways has been hypothesized to explain its beginning and recurrence over time. The majority of cases are defined as "idiopathic", reflecting our awkwardness to unravel the intimate mechanisms of RP. Given the possible occurrence of anti-nuclear, anti-heart and anti-intercalated disk antibodies as well as the association with peculiar human leukocyte antigen haplotypes, an autoimmune contribution has been claimed to specify the nature of RP. However, the most innovative pathogenic scenario of RP has been conferred to the innate immune system, mainly involving neutrophils and macrophages that produce a large amount of interleukin (IL)-1 via inflammasome activation. The clinical resemblance of RP with autoinflammatory diseases that may be marked by symptomatic serositis, high fevers and strikingly increased inflammatory parameters further suggests a similar inflammasome-mediated pathogenesis. Aspirin or non-steroidal anti-inflammatory drugs (NSAIDs) remain the mainstay of therapy in RP, whereas colchicine is recommended on top of standard anti-inflammatory therapy, due to its role in inhibiting the IL-1 converting enzyme (caspase 1) within the inflammasome as well as the release of additional pro-inflammatory mediators and reactive oxygen species. With regard to treatment of RP refractory to NSAIDs and colchicine, blockade of IL-1 is the most relevant advance achieved in the last decade: the outstanding effect of the short-acting IL-1 receptor antagonist anakinra has been first recognized in the pediatric population, giving a proof of its practical feasibility. Over a more recent time, a growing experience with anakinra deriving from both large and small studies has further confirmed that RP might be regarded as an IL-1-mediated disease. This review aims to provide a contemporary insight into the mechanisms leading to RP as well as into the most recent literature data showing the beneficial approach originating from IL-1 blockade in this intriguing disorder.
Keywords: Anakinra; Autoinflammation; Autoinflammatory disease; Innovative biotechnologies; Interleukin-1; Pericardial disease; Pericardium; Personalized medicine; Recurrent pericarditis.
Copyright © 2020. Published by Elsevier Inc.
Comment in
-
Editorial commentary: Recurrent pericarditis in the era of interleukin-1 inhibition.Trends Cardiovasc Med. 2021 Jul;31(5):275-276. doi: 10.1016/j.tcm.2020.04.010. Epub 2020 May 14. Trends Cardiovasc Med. 2021. PMID: 32417368 No abstract available.
Similar articles
-
Interleukin-1 Blockers for the Treatment of Recurrent Pericarditis: Pathophysiology, Patient-Reported Outcomes, and Perspectives.J Cardiovasc Pharmacol. 2024 Jun 1;83(6):503-510. doi: 10.1097/FJC.0000000000001435. J Cardiovasc Pharmacol. 2024. PMID: 37163222 Review.
-
Anakinra effectiveness in refractory polyserositis: An Italian multicenter study.Joint Bone Spine. 2022 Mar;89(2):105299. doi: 10.1016/j.jbspin.2021.105299. Epub 2021 Oct 14. Joint Bone Spine. 2022. PMID: 34656754
-
Failure of anti Interleukin-1 β monoclonal antibody in the treatment of recurrent pericarditis in two children.Pediatr Rheumatol Online J. 2020 Jun 16;18(1):51. doi: 10.1186/s12969-020-00438-5. Pediatr Rheumatol Online J. 2020. PMID: 32546242 Free PMC article.
-
Anakinra in Recurrent Pericarditis: Current Evidence on Clinical Use, Effectiveness, and Safety.J Cardiovasc Pharmacol. 2020 Jul;76(1):42-49. doi: 10.1097/FJC.0000000000000839. J Cardiovasc Pharmacol. 2020. PMID: 32265370 Review.
-
Treating Heart Inflammation With Interleukin-1 Blockade in a Case of Erdheim-Chester Disease.Front Immunol. 2018 Jun 1;9:1233. doi: 10.3389/fimmu.2018.01233. eCollection 2018. Front Immunol. 2018. PMID: 29910817 Free PMC article.
Cited by
-
Interleukin-1 Blockers: A Paradigm Shift in the Treatment of Recurrent Pericarditis.Life (Basel). 2024 Feb 26;14(3):305. doi: 10.3390/life14030305. Life (Basel). 2024. PMID: 38541631 Free PMC article. Review.
-
Comprehensive bioinformatics analysis and systems biology approaches to identify the interplay between COVID-19 and pericarditis.Front Immunol. 2024 Feb 22;15:1264856. doi: 10.3389/fimmu.2024.1264856. eCollection 2024. Front Immunol. 2024. PMID: 38455049 Free PMC article.
-
Interleukin-1 Blockers in Recurrent and Acute Pericarditis: State of the Art and Future Directions.Medicina (Kaunas). 2024 Jan 30;60(2):241. doi: 10.3390/medicina60020241. Medicina (Kaunas). 2024. PMID: 38399529 Free PMC article. Review.
-
Autoinflammatory Recurrent Pericarditis Associated with a New NLRP12 Mutation in a Male Adolescent.Life (Basel). 2023 Oct 28;13(11):2131. doi: 10.3390/life13112131. Life (Basel). 2023. PMID: 38004271 Free PMC article.
-
Can Asthma Cause Pericardial Effusion? Insights Into an Intriguing Association.Tex Heart Inst J. 2023 Mar 1;50(2):e227867. doi: 10.14503/THIJ-22-7867. Tex Heart Inst J. 2023. PMID: 37011363 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical